Medicamen Biotech's Q2 FY 2025-26 Quarterly Results

Result Summary

• Medicamen Biotech Ltd reported a 9.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 5.6%.
• Its expenses for the quarter were up by 8.4% QoQ and 4.1% YoY.
• The net profit increased 32.5% QoQ and increased 133.0% YoY.
• The earnings per share (EPS) of Medicamen Biotech Ltd stood at 1.56 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Medicamen Biotech Ltd is a pharmaceutical company engaged in the development, production, and distribution of a wide range of pharmaceutical products. The company primarily focuses on manufacturing medicines and healthcare products, including generic drugs, over-the-counter medicines, and specialty pharmaceuticals. Medicamen Biotech operates in the healthcare and pharmaceutical industry, which is characterized by rigorous regulatory standards and continuous innovation. The company is known for its commitment to quality and compliance with international standards in drug manufacturing. However, specific recent developments related to the company are not available in the provided data.

Revenue

During the second quarter of fiscal year 2026 (Q2FY26), Medicamen Biotech Ltd reported a total income of ₹47.54 crores, marking a quarter-over-quarter (QoQ) increase of 9.2% compared to ₹43.52 crores in Q1FY26. The year-over-year (YoY) growth in total income was 5.6% from ₹45.03 crores in Q2FY25. This revenue growth reflects the company's ability to enhance its sales and expand its market presence compared to both the previous quarter and the same quarter last year. The data demonstrates the company's continued focus on revenue generation and its capacity to capture market demand.

Profitability

Medicamen Biotech Ltd's profitability improved significantly in Q2FY26, as evidenced by the profit before tax (PBT) of ₹2.68 crores. This represents a QoQ growth of 25.8% from ₹2.13 crores in Q1FY26 and a YoY increase of 36.7% from ₹1.96 crores in Q2FY25. The company's profit after tax (PAT) also saw robust growth, reaching ₹2.12 crores in Q2FY26, which is a 32.5% increase QoQ from ₹1.60 crores in Q1FY26 and an impressive 133.0% YoY increase from ₹0.91 crores in Q2FY25. Despite an increase in tax expenses, which grew 7.5% QoQ from ₹0.53 crores in Q1FY26, the YoY tax expense decreased by 45.7% from ₹1.05 crores in Q2FY25, positively impacting net profitability.

Operating Metrics

The company's earnings per share (EPS) for Q2FY26 was ₹1.56, showing a QoQ growth of 32.2% from ₹1.18 in Q1FY26 and a YoY increase of 119.7% from ₹0.71 in Q2FY25. Total expenses for the quarter amounted to ₹44.86 crores, increasing 8.4% QoQ from ₹41.38 crores in Q1FY26 and 4.1% YoY from ₹43.08 crores in Q2FY25. These figures indicate an efficient management of expenses relative to revenue growth, contributing to the company's strong financial performance. The overall financial data for Q2FY26 suggests a positive trend in the company's operational efficiency and financial health.